GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » Additional Paid-In Capital

Arecor Therapeutics (LSE:AREC) Additional Paid-In Capital : £28.98 Mil(As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics Additional Paid-In Capital?


Arecor Therapeutics's quarterly additional paid-in capital stayed the same from Dec. 2022 (£28.98 Mil) to Jun. 2023 (£28.98 Mil) and stayed the same from Jun. 2023 (£28.98 Mil) to Dec. 2023 (£28.98 Mil).

Arecor Therapeutics's annual additional paid-in capital increased from Dec. 2021 (£23.35 Mil) to Dec. 2022 (£28.98 Mil) but then stayed the same from Dec. 2022 (£28.98 Mil) to Dec. 2023 (£28.98 Mil).

Arecor Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Arecor Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arecor Therapeutics Additional Paid-In Capital Chart

Arecor Therapeutics Annual Data
Trend May17 May18 May19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 11.59 11.59 23.35 28.98 28.98

Arecor Therapeutics Semi-Annual Data
May18 May19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.35 23.35 28.98 28.98 28.98

Arecor Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Arecor Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Arecor Therapeutics (LSE:AREC) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » Additional Paid-In Capital
Comparable Companies
LSE:ETX LSE:4BB LSE:DEST LSE:SBTX LSE:OBD LSE:SAR LSE:TRX LSE:C4XD LSE:FUM LSE:POLB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
6UI:Germany
Address
Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Website
https://www.arecor.com
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.